The invention relates to methods for the treatment of migraine with aura and the prevention of pain in migraine with aura that include the administration at aura of a NOS inhibitor, e.g., substituted indole compounds that inhibit NOS (e.g., Compounds (l)-(54) and compounds described by Formulas (I), (I-A), or (1-B)). These indole compounds can also have a superior cardiovascular profile compared to triptan migraine therapeutics (e.g., sumatriptan), and these methods can be useful for migraineurs who have, or are at risk for, cardiovascular, neurological, or psychological diseases or conditions. The indole compounds described herein can also be used for the treatment or prevention of cortical spreading depression (CSD) or tactile allodynia.
展开▼
